Multimodal treatment of desmoid tumours: The significance of local control

Clinical and Translational Oncology

Volumn 13, Issue 3, 2011, Pages 189-193

  Pajares, Bella ^a   Torres, Esperanza ^a   Jiménez, Begoña ^a   Sevilla, Isabel ^a   Rodríguez, Ana ^a   Rico, José Manuel ^a   Trigo, José Manuel ^a   Alba, Emilio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Desmoid tumours; FAP; Fibromatosis

Indexed keywords

METHOTREXATE; SULINDAC; TAMOXIFEN; VINBLASTINE;

ABDOMINAL TUMOR; ADENOMATOUS POLYP; ADOLESCENT; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DESMOID TUMOR; DISEASE FREE SURVIVAL; DRUG EFFECT; FAMILIAL CANCER; FEMALE; FIBROMATOSIS; FOLLOW UP; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RARE DISEASE; RECURRENT CANCER; RETROSPECTIVE STUDY; RISK ASSESSMENT; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FIBROMATOSIS, AGGRESSIVE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79958195837     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0639-4     Document Type: Article

References (29)

1. Spear MA, Jennings LC, Mankin HJ et al (1998) Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys 40:637-645
2. Merchant NB, Lewis JJ, Woodruff JM et al (1999) Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer 86:2045-2052
3. Lev D, Kotilingam D, Wei C et al (2007) Optimizing treatment of desmoid tumors. J Clin Oncol 25:1785-1791 (Pubitemid 46797962)
4. Wong SL (2008) Diagnosis and management of desmoid tumors and fibrosarcoma J Surg Oncol 97:554-558
5. Lewis JJ, Boland PJ, Leung DHY et al (1999) The enigma of desmoid tumors. Ann Surg 229:866-872; discussion 872-873
6. Sturt NJ, Gallagher MC, Bassett P et al (2004) Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline APC mutation. Gut 53:1832-1836 (Pubitemid 39556906)
7. Tejpar S, Nollet F, Li C et al (1999) Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 18:6615-6620
8. Dinauer PA, Brixey CJ, Moncur JT et al (2007) Pathologic and MR imaging features of benign fibrous soft-tissue tumors in adults. Radiographics 27:173-187
9. Posner MC, Shiu MH, Newsome JL et al (1989) The desmoid tumor. Not a benign disease. Arch Surg 124:191-196
10. Ballo MT, Zagars GK, Pollack A (1998) Radiation therapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys 42:1007-1014 (Pubitemid 29004142)
11. Gronchi A, Casali PG, Mariani L et al (2003) Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol 21:1390-1397 (Pubitemid 46606421)
12. Jelinek JA, Stelzer KJ, Conrad E et al (2001) The efficacy of radiotherapy as postoperative treatment for desmoid tumors. Int J Radiat Oncol Biol Phys 50:121-125
13. Zlotecki RA, Scarborough MT, Morris CG et al (2002) External beam radiotherapy for primary and adjuvant management of aggressive fibromatosis. Int J Radiat Oncol Biol Phys 54:177-181
14. Micke O, Seegenschmiedt MH (2005) Radiation therapy for aggressive fibromatosis (desmoid tumors): results of a national Patterns of Care Study. Int J Radiat Oncol Biol Phys 61:882-891 (Pubitemid 40247987)
15. McAdam WA, Goligher JC (1970) The occurrence of desmoids in patients with familial polyposis coli. Br J Surg 57:618-631
16. Reitamo JJ, Scheinin TM, Hayry P (1986) The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor. Am J Surg 151:230-237 (Pubitemid 16107305)
17. Rock MG, Pritchard DJ, Reiman HM et al (1984) Extra-abdominal desmoid tumors. J Bone Joint Surg Am 66:1369-1374 (Pubitemid 15177122)
18. Procter H, Singh L, Baum M, Brinkley D (1987) Response of multicentric desmoid tumours to tamoxifen. Br J Surg 74:401 (Pubitemid 17080897)
19. Brooks MD, Ebbs SR, Colletta AA, Baum M (1992) Desmoid tumours treated with triphenylethylenes. Eur J Cancer 28A:1014-1018
20. Klein WA, Miller HH, Anderson M, DeCosse JJ (1987) The use of indomethacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with familial polyposis. Cancer 60:2863-2868 (Pubitemid 18005855)
21. Izes JK, Zinman LN, Larsen CR (1996) Regression of large pelvic desmoid tumor by tamoxifen and sulindac. Urology 47:756-759 (Pubitemid 26172750)
22. Lackner H, Urban C, Kerbl R et al (1997) Noncytotoxic drug therapy in children with unresectable desmoid tumors. Cancer 80:334-340 (Pubitemid 27282328)
23. Tsukada K, Church JM, Jagelman DG et al (1992) Noncytotoxic drug therapy for intra-abdominal desmoid tumor in patients with familial adenomatous polyposis. Dis Colon Rectum 35:29-33
24. Pilz T, Pilgrim TB, Bisogno G et al (1999) [Chemotherapy in fibromatoses of childhood and adolescence: results from the Cooperative soft tissue sarcoma study (CWS) and the Italian Cooperative study group (ICG-AIEOP)]. Klin Padiatr 211:291-295 (Pubitemid 29364770)
25. Weiss AJ, Lackman RD (1989) Low-dose chemotherapy of desmoid tumors. Cancer 64:1192-1194 (Pubitemid 19217093)
26. Azzarelli A, Gronchi A, Bertulli R et al (2001) Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 92:1259-1264
27. Mace J, Sybil Biermann J, Sondak V et al (2002) Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 95:2373-2379 (Pubitemid 35351145)
28. Heinrich MC, McArthur GA, Demetri GD et al (2006) Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 24:1195-1203 (Pubitemid 46638818)
29. Heinrich MC, Joensuu H, Demetri GD et al (2008) Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 14:2717-2725